Vimian Group AB (publ) (STO:VIMIAN)

Market Cap	15.93B
Revenue (ttm)	4.65B
Net Income (ttm)	348.26M
Shares Out	526.90M
EPS (ttm)	0.66
PE Ratio	45.57
Forward PE	23.37
Dividend	n/a
Ex-Dividend Date	n/a

Volume	104,156
Average Volume	347,691
Open	29.92
Previous Close	29.94
Day's Range	29.92 - 30.70
52-Week Range	27.80 - 47.30
Beta	1.51
RSI	51.61
Earnings Date	Feb 12, 2026

About Vimian Group AB

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the I...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 1,200
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: VIMIAN

Financial Performance

In 2024, Vimian Group AB's revenue was 374.80 million, an increase of 12.99% compared to the previous year's 331.70 million. Earnings were 18.50 million, an increase of 88.78%.

Financial numbers in EUR